Heron Therapeutics (HRTX) Tops Q1 EPS by 5c ; Offers Guidance

Heron Therapeutics (NASDAQ: HRTX) reported Q1 EPS of ($0.02), $0.05 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $34.7 million versus the consensus estimate of $32.81 million.

GUIDANCE:

Heron Therapeutics sees FY2024 revenue of $138-158 million, versus the consensus of $144.9 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• Lucid reports Q2 output, names new CFO and five other leaders
• Rivian raises 2026 delivery outlook after Q2 results top guidance
• AI chip winners may face tougher road ahead as hyperscalers catch up: JPM